Prioritising anticancer drugs for environmental monitoring and risk assessment purposes

Science of the Total Environment

Volumn 473-474, Issue , 2014, Pages 159-170

  Booker, Victoria ^a   Halsall, Crispin ^a   Llewellyn, Neville ^b   Johnson, Andrew ^b   Williams, Richard ^b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

Author keywords

Fate; Pharmaceuticals; Surface water; Wastewater

Indexed keywords

CHEMICALS; CHEMOTHERAPY; DRUG PRODUCTS; RISK ASSESSMENT; WASTEWATER; WASTEWATER TREATMENT;

ANTICANCER DRUG; AQUATIC SYSTEM; ECOLOGICAL IMPACTS; ENVIRONMENTAL MONITORING; FATE; OBSERVATIONAL STUDY; PHYSICAL-CHEMICAL PROPERTIES; URINARY EXCRETION;

SURFACE WATERS;

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; LAPATINIB; METHOTREXATE; MITOTANE; PACLITAXEL; SURFACE WATER; TREOSULFAN;

CONCENTRATION (COMPOSITION); DRUG; ENVIRONMENTAL FATE; ENVIRONMENTAL MONITORING; PHYSICOCHEMICAL PROPERTY; RISK ASSESSMENT; SURFACE WATER; TOXICITY; WASTEWATER;

AQUATIC ENVIRONMENT; ARTICLE; BIODEGRADATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOCIATION; DRUG EXCRETION; DRUG METABOLISM; DRUG USE; ECOTOXICITY; ENVIRONMENTAL IMPACT ASSESSMENT; ENVIRONMENTAL MONITORING; GENOTOXICITY; HOSPITAL WASTE; PHYSICAL CHEMISTRY; POLLUTION TRANSPORT; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; URINARY EXCRETION; WASTE WATER MANAGEMENT; WATER CONTAMINATION;

ENGLAND; UNITED KINGDOM;

FATE; PHARMACEUTICALS; SURFACE WATER; WASTEWATER;

ANTINEOPLASTIC AGENTS; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; RISK ASSESSMENT; WASTE DISPOSAL, FLUID; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84890867781     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2013.11.145     Document Type: Article

References (69)

1. Aherne G.W., English J., et al. The role of immunoassay in the analysis of microcontaminants in water samples. Ecotoxicol Environ Saf 1985, 9(1):79-83.
2. Aherne G.W., Hardcastle A., et al. Cytotoxic drugs and the aquatic environment: estimation of bleomycin in river and water samples. J Pharm Pharmacol 1990, 42(10):741-742.
3. Al-Ahmad A., Kummerer K. Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment. Cancer Detect Prev 2001, 25(1):102-107.
4. AlAhmad A., Kummerer K., et al. Biodegradation and toxicity of the antineoplastics mitoxantron hydrochloride and treosulfane in the closed bottle test (OECD 301 D). Bull Environ Contam Toxicol 1997, 58(5):704-711.
5. Ardizzoni A., Antonelli G., et al. The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). Ann Oncol 1999, 10(Suppl. 5):S13-S17.
6. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333(1-3):167-184.
7. Backhaus T., Grimme L.H. The toxicity of antibiotic agents to the luminescent bacterium Vibrio fischeri. Chemosphere 1999, 38(14):3291-3301.
8. Bantle J.A., F.R., Burton D.T., Fort D.J., Dawson D.A., Linder G., et al. FETAX interlaboratory validation study: phase III-part 1 testing. J Appl Toxicol 1996, 16(6):517-528.
9. Besse J.-P., Latour J.-F., et al. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39(1):73-86.
10. Buerge I.J., Buser H.-R., et al. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters†. Environ Sci Technol 2006, 40(23):7242-7250.
11. Caley A., Jones R. The principles of cancer treatment by chemotherapy. Surgery (Oxford) 2012, 30(4):186-190.
12. Castiglioni S., Bagnati R., et al. A multiresidue analytical method using solid-phase extraction and high-pressure liquid chromatography tandem mass spectrometry to measure pharmaceuticals of different therapeutic classes in urban wastewaters. J Chromatogr A 2005, 1092(2):206-215.
13. Coetsier C.M., et al. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ Int 2009, 35(5):787-792.
14. Daughton C.G. Environmental stewardship and drugs as pollutants. Lancet 2002, 360(9339):1035-1036.
15. Deenen M.J., Cats A., et al. Part 3: pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist 2011, 16(7):992-1005.
16. Du B., Price A.E., et al. Comparison of contaminants of emerging concern removal, discharge, and water quality hazards among centralized and on-site wastewater treatment system effluents receiving common wastewater influent. Sci Total Environ 2014, 466-467:976-984.
17. EMA Alimta: EPAR-scientific discussion Retrieved 02/06/2011, 2011, from. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000564/WC500025606.pdf.
18. Ferk F., Misík M., et al. Genotoxic effects of wastewater from an oncological ward. Mutat Res Genet Toxicol Environ Mutagen 2009, 672(2):69-75.
19. Garcia-Ac Araceli, a.P.A.S., a, Gagnonb Christian, Sauve Sebastien Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry. J Environ Monit 2009, 11:830-838.
20. Garcia-Ac A., Broséus R., et al. Oxidation kinetics of cyclophosphamide and methotrexate by ozone in drinking water. Chemosphere 2010, 79(11):1056-1063.
21. Giuliani F., Koller T., et al. Detection of genotoxic activity in native hospital waste water by the umuC test. Mutat Res Genet Toxicol 1996, 368(1):49-57.
22. Gómez-Canela C., Cortés-Francisco N., et al. Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry. Environ Sci Pollut Res 2012, 19(8):3210-3218.
23. Halling-Sørensen B., Nors Nielsen S., et al. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998, 36(2):357-393.
24. Henschel K.P., Wenzel A., et al. Environmental hazard assessment of pharmaceuticals. Regul Toxicol Pharmacol 1997, 25(3):220-225.
25. Henschela K.-P., A.W., Diedricha M., Fliednerb A. Environmental hazard assessment of pharmaceuticals. Regul Toxicol Pharmacol 1997, 25(3):220-225.
26. Hörsing M., Ledin A., et al. Determination of sorption of seventy-five pharmaceuticals in sewage sludge. Water Res 2011, 45(15):4470-4482.
27. Johnson A.C., Jürgens M.D., et al. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348(1-2):167-175.
28. Jones O.A., Lester J.N., et al. Pharmaceuticals: a threat to drinking water?. Trends Biotechnol 2005, 23(4):163-167.
29. Kiffmeyer T., Götze H.-J., et al. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius J Anal Chem 1998, 361(2):185-191.
30. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. TrAC Trends Anal Chem 2011, 30(7):1065-1087.
31. Kovalova L. Cytostatics in the aquatic environment: analysis, occurrence, and possibilities for removal 2009, Aachen University.
32. Kovalova L., McArdell C.S., et al. Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. J Chromatogr A 2009, 1216(7):1100-1108.
33. Kummerer K. Pharmaceuticals in the environment: sources, fate, effects and risks 2001, Springer-Verlag Berlin and Heidelberg GmbH & Co. K.
34. Kummerer K., Al-Ahmad A. Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine, and gemcitabine: impact of the chemical structure and synergistic toxicity with hospital effluent. Acta Hydrochim Hydrobiol 1997, 25(4):166-172.
35. Kümmerer K., Steger-Hartmann T., et al. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res 1997, 31(11):2705-2710.
36. Kümmerer K., Al-Ahmad A., et al. Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry. Chemosphere 2000, 40(7):767-773.
37. Lambert J.C., Lipscomb J.C. Mode of action as a determining factor in additivity models for chemical mixture risk assessment. Regul Toxicol Pharmacol 2007, 49(3):183-194.
38. Lenz K., et al. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 2007, 69(11):1765-1774.
39. Leung H.W., Minh T.B., et al. Distribution, fate and risk assessment of antibiotics in sewage treatment plants in Hong Kong, South China. Environ Int 2012, 42:1-9.
40. Lin A.Y.-C., Reinhard M. Photodegradation of common environmental pharmaceuticals and estrogens in river water. Environ Toxicol Chem 2005, 24(6):1303-1309.
41. Llewellyn N., Lloyd P., et al. Determination of cyclophosphamide and ifosfamide in sewage effluent by stable isotope-dilution liquid chromatography-tandem mass spectrometry. J Chromatogr A 2011, 1218(47):8519-8528.
42. Mahnik S.N., Rizovski B., et al. Determination of 5-fluorouracil in hospital effluents. Anal Bioanal Chem 2004, 380(1):31-35.
43. Mahnik S.N., Rizovski B., et al. Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere 2006, 65(8):1419-1425.
44. Mahnik S.N., Lenz K., et al. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66(1):30-37.
45. Mahoney B.P., et al. Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003, 66(7):1207-1218.
46. Martín J., Camacho-Muñoz D., Santos J.L., Aparicio I., Alonso E. Simultaneous determination of a selected group of cytostatic drugs in water using high-performance liquid chromatography-triple-quadrupole mass spectrometry. J Sep Sci 2011, 34:3166-3177.
47. McCall P.J., Swann R.L., et al. Estimation of chemical mobility in soil from liquid chromatographic retention times. Bull Environ Contam Toxicol 1980, 24(1):190-195.
48. Moldovan Z. Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania. Chemosphere 2006, 64(11):1808-1817.
49. Ocampo-Pérez R., Sánchez-Polo M., et al. Degradation of antineoplastic cytarabine in aqueous phase by advanced oxidation processes based on ultraviolet radiation. Chem Eng J 2010, 165(2):581-588.
50. Radka Zounková P.O., Doležalová Lenka, Hilscherová Klára, Maršálek Blahoslav, Bláha Luděk Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 2009, 26(10):2208-2214.
51. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356(1-3):143-153.
52. Rowney N.C., Johnson A.C., et al. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009, 28(12):2733-2743.
53. Sanderson H., Johnson D.J., et al. Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids and algae by ECOSAR screening. Toxicol Lett 2003, 144(3):383-395.
54. Sottani C., et al. Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubcin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation. Rapid Commun Mass Spectrom 2008, 22(17):2645-2659.
55. Stanford B.D., Weinberg H.S. Evaluation of on-site wastewater treatment technology to remove estrogens, nonylphenols, and estrogenic activity from wastewater. Environ Sci Technol 2010, 44(8):2994-3001.
56. StegerHartmann T., Kummerer K., et al. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by two-step solid-phase extraction and gas chromatography mass spectrometry. J Chromatogr A 1996, 726(1-2):179-184.
57. Steger-Hartmann T., Kümmerer K., et al. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol Environ Saf 1997, 36(2):174-179.
58. Stevens-Garmon J., Drewes J.E., et al. Sorption of emerging trace organic compounds onto wastewater sludge solids. Water Res 2011, 45(11):3417-3426.
59. Straub J.O. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe. Integr Environ Assess Manag 2010, 6(S1):540-566.
60. Strong R., H., CJ, Jones K.C., Martin F.L. Environmentally relevant levels of the genotoxin, cyclophosphamide induce alterations in MCF-7 cells detectable by biospectroscopy approaches. Mutagenesis 2012, 27:814.
61. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 32(11):3245-3260.
62. Thomas K.V., et al. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 2007, 9(12):1410-1418.
63. Valcárcel Y., González Alonso S., Rodríguez-Gil J.L., Gil A., Catalá M. Detection of pharmaceutically active compounds in the rivers and tap water of the Madrid Region (Spain) and potential ecotoxicological risk. Chemosphere 2011, 84(10):1336-1348.
64. Wang L., Albasi C., et al. Cyclophosphamide removal from water by nanofiltration and reverse osmosis membrane. Water Res 2009, 43(17):4115-4122.
65. Weylandt K.H., et al. ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. Mol Cancer Ther 2007, 6(3):979-986.
66. Yamamoto H., Nakamura Y., et al. Persistence and partitioning of eight selected pharmaceuticals in the aquatic environment: laboratory photolysis, biodegradation, and sorption experiments. Water Res 2009, 43(2):351-362.
67. Yin J., Shao B., et al. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull Environ Contam Toxicol 2010, 84(1):39-45.
68. Zounkova R., Kovalova L., et al. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81(2):253-260.
69. Zuccato E., Calamari D., et al. Presence of therapeutic drugs in the environment. Lancet 2000, 355(9217):1789-1790.